




PHARMACEUTICAL 2021

CHIASMA INC
Rank 225 of 409





PHARMACEUTICAL 2021

CHIASMA INC
Rank 225 of 409

The relative strengths and weaknesses of CHIASMA INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CHIASMA INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 71% points. The greatest weakness of CHIASMA INC is the variable Net Income, reducing the Economic Capital Ratio by 57% points.

The company's Economic Capital Ratio, given in the ranking table, is -155%, being 199% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	153,358
Cost of Goods Sold	61
Intangible Assets	0
Liabilities, Current	16,731
Liabilities, Non-Current	0
Other Assets	22,446
Other Compr. Net Income	-37
Other Expenses	5,956
Other Liabilities	67,822
Other Net Income	0
Property and Equipment	534
Research and Development	26,802
Revenues	2,932
Selling, General and Administrative Expense	44,892

Output Variable	Value in 1000 USD
Assets	176,338
Liabilities	84,553
Expenses	77,711
Stockholders Equity	91,785
Net Income	-74,779
Comprehensive Net Income	-74,798
Economic Capital Ratio	-155%

